Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07493512 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

StatusRecruiting
PhasePhase 1
SponsorAmgen
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years 6 months later Jan 30, 2028 → Jul 30, 2030
See other at-risk trials from Amgen

Record History

  1. Primary completion pushed from Jan 30, 2028 to Jul 30, 2030 Trial sites expanded: 11 → 14 locations · Eligibility criteria expanded, about 23 words Show 2 more changesShow less
    • Trial sites expanded: 11 → 14 locations
    • Eligibility criteria expanded, about 23 words
  2. Study sites: 10 to 11v8
  3. Trial sites expanded: 5 → 10 locationsv7
  4. Study sites: 4 to 5v6
  5. Study sites: 3 to 4v5
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 2 to 3v4
  2. Study sites: 1 to 2v3
  1. Primary completion pushed from May 27, 2027 to Jan 30, 2028 Recruitment opened · Completion pushed from Nov 24, 2029 to Jul 30, 2030 · Study sites: 0 to 1 · 1 morev2 Show 4 more changesShow less
    • Recruitment opened
    • Completion pushed from Nov 24, 2029 to Jul 30, 2030
    • Study sites: 0 to 1
    • Start date changed from estimate of May 26, 2026 to Apr 28, 2026
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Amgen
168 trials monitored
See 11 trials at risk
Prostate Cancer
2,487 trials monitored
See 160 trials at risk
The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).
Trial Details
NCT Number NCT07493512
Lead Sponsor Amgen
Conditions Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov